On September 19, 2019 Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers, reported that a poster will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper), being held in Barcelona, Spain from September 27 to October 1, 2019 (Press release, Ayala Pharmaceuticals, SEP 19, 2019, View Source [SID1234539647]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation information is as follows:
Title: ACCURACY a phase (P) 2 trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notchact mut): preliminary safety and efficacy data
Session Title: Poster Display Session
Session Date and Time: Monday, September 30, 2019 at 12:00pm to 1:00pm CET
Presentation Number: 1148P
Location: Poster Area (Hall 4)
Presenter: Alan L. Ho, M.D., Ph.D., Memorial Sloan Kettering Cancer Center